Cell death signaling and anticancer therapy

Frontiers in Oncology

Volumn 1, Issue MAY, 2011, Pages

  Galluzzi, Lorenzo ^a,b,c   Vitale, Ilio ^a,b,c   Vacchelli, Erika ^a,b,c   Kroemer, Guido ^a,b,d,e,f  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Caspases; Lysosomal membrane permeabilization; Mitochondrial membrane permeabilization; Necrosome; Oncosis; Phosphatidylserine; Reactive oxygen species; RIP1

Indexed keywords

EID: 84875533995     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00005     Document Type: Review

References (262)

1. Aapro, M. S., Conte, P., Esteban Gonzalez, E., and Trillet-Lenoir, V. (2007). Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 67, 657-667.
2. Antosiewicz, J., Ziolkowski, W., Kaczor, J. J., and Herman-Antosiewicz, A. (2007). Tumor necrosis factor-alpha-induced reactive oxygen species formation is mediated by JNK1-dependent ferritin degradation and elevation of labile iron pool. Free Radic. Biol. Med. 43, 265-270.
3. Awasthi, N., Kirane, A., Schwarz, M. A., Toombs, J. E., Brekken, R. A., and Schwarz, R. E. (2011). Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer 11, 15. doi: 10.1186/1471-2407-11-15
4. Barry, M. A., Behnke, C. A., and Eastman, A. (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362.
5. Begleiter, A., Lee, K., Israels, L. G., Mowat, M. R., and Johnston, J. B. (1994). Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 8(Suppl. 1), S103-S106.
6. Bello, C., and Sotomayor, E. M. (2007). Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematol. Am. Soc. Hematol. Educ. Program. 233-242.
7. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'Reilly, T., Natt, F., Hall, J., Lane, H. A., and Thomas, G. (2005). The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759.
8. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Grant, S., Bullock, G., Huang, Y., Ponnathpur, V., and Mahoney, M. E. (1993). High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82, 3133-3140.
9. Billard, C., Kern, C., Tang, R., Ajchenbaum-Cymbalista, F., and Kolb, J. P. (2003). Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17, 2435-2443.
10. Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., O'Connor, P., and Anderes, K. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7, 2394-2404.
11. Bonvini, P., Zorzi, E., Basso, G., and Rosolen, A. (2007). Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30 + anaplastic large cell lymphoma. Leukemia 21, 838-842.
12. Boor, P. P., Metselaar, H. J., Mancham, S., Tilanus, H. W., Kusters, J. G., and Kwekkeboom, J. (2006). Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am. J. Transplant. 6, 2332-2341.
13. Bown, S. G., Rogowska, A. Z., Whitelaw, D. E., Lees, W. R., Lovat, L. B., Ripley, P., Jones, L., Wyld, P., Gillams, A., and Hatfield, A. W. (2002). Photodynamic therapy for cancer of the pancreas. Gut 50, 549-557.
14. Boya, P., and Kroemer, G. (2008). Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434-6451.
15. Brouckaert, G., Kalai, M., Krysko, D. V., Saelens, X., Vercammen, D., Ndlovu, M., Haegeman, G., D'Herde, K., and Vandenabeele, P. (2004). Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell 15, 1089-1100.
16. Brown, D. G., Sun, X. M., and Cohen, G. M. (1993). Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J. Biol. Chem. 268, 3037-3039.
17. Budgin, J. B., Richardson, S. K., Newton, S. B., Wysocka, M., Zaki, M. H., Benoit, B., and Rook, A. H. (2005). Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch. Dermatol. 141, 315-321.
18. Bundred, N., and Howell, A. (2002). Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev. Anticancer Ther. 2, 151-160.
19. Busby, E. C., Leistritz, D. F., Abraham, R. T., Karnitz, L. M., and Sarkaria, J. N. (2000). The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60, 2108-2112.
20. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. (1998). Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92, 3804-3816.
21. Cao, C., Han, Y., Ren, Y., and Wang, Y. (2009). Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell. Mol. Immunol. 6, 469-475.
22. Cardarelli, P. M., Quinn, M., Buckman, D., Fang, Y., Colcher, D., King, D. J., Bebbington, C., and Yarranton, G. (2002). Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51, 15-24.
23. Carnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., and Goldenberg, D. M. (2007). Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol. 44, 1331-1341.
24. Carpinelli, P., Ceruti, R., Giorgini, M. L., Cappella, P., Gianellini, L., Croci, V., Degrassi, A., Texido, G., Rocchetti, M., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Arrigoni, C., Soncini, C., Alli, C., Patton, V., Marsiglio, A., Ballinari, D., Pesenti, E., Fancelli, D., and Moll, J. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6, 3158-3168.
25. Carrasco, R. A., Stamm, N. B., Marcusson, E., Sandusky, G., Iversen, P., and Patel, B. K. (2011). Antisense inhibition of survivin expression as a cancer therapeutic. Mol. Cancer Ther. 10, 221-232.
26. Cartron, G., Watier, H., Golay, J., and Solal-Celigny, P. (2004). From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635-2642.
27. Casale, F., Addeo, R., D'Angelo, V., Indolfi, P., Poggi, V., Morgera, C., Crisci, S., and Di Tullio, M. T. (2003). Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Int. J. Oncol. 22, 123-128.
28. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., Coutant, F., Métivier, D., Pichard, E., Aucouturier, P., Pierron, G., Garrido, C., Zitvogel, L., and Kroemer, G. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701.
29. Caserini, C., Pratesi, G., Tortoreto, M., Bedogne, B., Carenini, N., Supino, R., Perego, P., Righetti, S. C., and Zunino, F. (1997). Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin. Cancer Res. 3, 955-961.
30. Castedo, M., Coquelle, A., Vivet, S., Vitale, I., Kauffmann, A., Dessen, P., Pequignot, M. O., Casares, N., Valent, A., Mouhamad, S., Schmitt, E., Modjtahedi, N., Vainchenker, W., Zitvogel, L., Lazar, V., Garrido, C., and Kroemer, G. (2006). Apoptosis regulation in tetraploid cancer cells. EMBO J. 25, 2584-2595.
31. Castedo, M., Ferri, K. F., and Kroemer, G. (2002). Mammalian target of rapamycin (mTOR): pro-and anti-apoptotic. Cell Death Differ. 9, 99-100.
32. Chauhan, D., Singh, A. V., Ciccarelli, B., Richardson, P. G., Palladino, M. A., and Anderson, K. C. (2010). Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115, 834-845.
33. Cheson, B. D. (2010). Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28, 3525-3530.
34. Cheung, C. H., Coumar, M. S., Hsieh, H. P., and Chang, J. Y. (2009). Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin. Investig. Drugs 18, 379-398.
35. Chipuk, J. E., and Green, D. R. (2005). Do inducers of apoptosis trigger caspase-independent cell death? Nat. Rev. Mol. Cell Biol. 6, 268-275.
36. Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., and Chan, F. K. (2009). Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123.
37. Ciccolini, J., Fina, F., Bezulier, K., Giacometti, S., Roussel, M., Evrard, A., Cuq, P., Romain, S., Martin, P. M., and Aubert, C. (2002). Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol. Cancer Ther. 1, 923-927.
38. Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M. L., Sola, F., Cappella, P., Perrera, C., Depaolini, S. R., Rusconi, L., Cucchi, U., Avanzi, N., Bertrand, J. A., Bossi, R. T., Pesenti, E., Galvani, A., Isacchi, A., Colotta, F., Donati, D., and Moll, J. (2010). Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 70, 10255-10264.
39. Cosse, J. P., Sermeus, A., Vannuvel, K., Ninane, N., Raes, M., and Michiels, C. (2007). Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol. Cancer 6, 61.
40. Crazzolara, R., Cisterne, A., Thien, M., Hewson, J., Baraz, R., Bradstock, K. F., and Bendall, L. J. (2009). Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113, 3297-3306.
41. da Silva, C. P., de Oliveira, C. R., da Conceicao, M., and de Lima, P. (1996). Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol. 51, 1331-1340.
42. Dai, Y., and Grant, S. (2010). New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16, 376-383.
43. Dalle, S., Reslan, L., Besseyre de Horts, T., Herveau, S., Herting, F., Plesa, A., Friess, T., Umana, P., Klein, C., and Dumontet, C. (2011). Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10, 178-185.
44. Dancey, J., and Steward, W. P. (1995). The role of vindesine in oncology-recommendations after 10 years' experience. Anticancer Drugs 6, 625-636.
45. Dar, A. A., Goff, L. W., Majid, S., Berlin, J., and El-Rifai, W. (2010). Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol. Cancer Ther. 9, 268-278.
46. De Botton, S., Sabri, S., Daugas, E., Zermati, Y., Guidotti, J. E., Hermine, O., Kroemer, G., Vainchenker, W., and Debili, N. (2002). Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 100, 1310-1317.
47. De Geest, K., Blessing, J. A., Morris, R. T., Yamada, S. D., Monk, B. J., Zweizig, S. L., Matei, D., Muller, C. Y., and Richards, W. E. (2010). Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J. Clin. Oncol. 28, 149-153.
48. Degenhardt, Y., and Lampkin, T. (2010). Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res. 16, 384-389.
49. Dezube, B. J. (2000). New therapies for the treatment of AIDS-related Kaposi sarcoma. Curr. Opin. Oncol. 12, 445-449.
50. Dineen, S. P., Roland, C. L., Greer, R., Carbon, J. G., Toombs, J. E., Gupta, P., Bardeesy, N., Sun, H., Williams, N., Minna, J. D., and Brekken, R. A. (2010). Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 70, 2852-2861.
51. Dubois, E. A., and Cohen, A. F. (2009). Panitumumab. Br. J. Clin. Pharmacol. 68, 482-483.
52. Dumontet, C., and Jordan, M. A. (2010). Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790-803.
53. Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., Lysiak, J. J., Harden, T. K., Leitinger, N., and Ravichandran, K. S. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286.
54. Eom, Y. W., Kim, M. A., Park, S. S., Goo, M. J., Kwon, H. J., Sohn, S., Kim, W. H., Yoon, G., and Choi, K. S. (2005). Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24, 4765-4777.
55. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R. M., and TARGET Study Group. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134.
56. Fantin, V. R., and Richon, V. M. (2007). Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin. Cancer Res. 13, 7237-7242.
57. Felip, E., Rojo, F., Reck, M., Heller, A., Klughammer, B., Sala, G., Cedres, S., Peralta, S., Maacke, H., Foernzler, D., Parera, M., Möcks, J., Saura, C., Gatzemeier, U., and Baselga, J. (2008). A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin. Cancer Res. 14, 3867-3874.
58. Foster, F. M., Owens, T. W., Tanianis-Hughes, J., Clarke, R. B., Brennan, K., Bundred, N. J., and Streuli, C. H. (2009). Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 11, R41.
59. Frampton, J. E., and Moen, M. D. (2010). Vinflunine. Drugs 70, 1283-1293.
60. Fujimura, S., Suzumiya, J., Anzai, K., Ohkubo, K., Hata, T., Yamada, Y., Kamihira, S., Kikuchi, M., and Ono, J. (1998). Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk. Res. 22, 611-618.
61. Galluzzi, L., Aaronson, S. A., Abrams, J., Alnemri, E. S., Andrews, D. W., Baehrecke, E. H., Bazan, N. G., Blagosklonny, M. V., Blomgren, K., Borner, C., Bredesen, D. E., Brenner, C., Castedo, M., Cidlowski, J. A., Ciechanover, A., Cohen, G. M., De Laurenzi, V., De Maria, R., Deshmukh, M., Dynlacht, B. D., El-Deiry, W. S., Flavell, R. A., Fulda, S., Garrido, C., Golstein, P., Gougeon, M. L., Green, D. R., Gronemeyer, H., Hajnóczky, G., Hardwick, J. M., Hengartner, M. O., Ichijo, H., Jäättelä, M., Kepp, O., Kimchi, A., Klionsky, D. J., Knight, R. A., Kornbluth, S., Kumar, S., Levine, B., Lipton, S. A., Lugli, E., Madeo, F., Malomi, W., Marine, J. C., Martin, S. J., Medema, J. P., Mehlen, P., Melino, G., Moll, U. M., Morselli, E., Nagata, S., Nicholson, D. W., Nicotera, P., Nuñez, G., Oren, M., Penninger, J., Pervaiz, S., Peter, M. E., Piacentini, M., Prehn, J. H., Puthalakath, H., Rabinovich, G. A., Rizzuto, R., Rodrigues, C. M., Rubinsztein, D. C., Rudel, T., Scorrano, L., Simon, H. U., Steller, H., Tschopp, J., Tsujimoto, Y., Vandenabeele, P., Vitale, I., Vousden, K. H., Youle, R. J., Yuan, J., Zhivotovsky, B., and Kroemer, G. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093-1107.
62. Galluzzi, L., Joza, N., Tasdemir, E., Maiuri, M. C., Hengartner, M., Abrams, J. M., Tavernarakis, N., Penninger, J., Madeo, F., and Kroemer, G. (2008). No death without life: vital functions of apoptotic effectors. Cell Death Differ. 15, 1113-1123.
63. Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., and Kroemer, G. (2007). Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 14, 1237-1243.
64. Galmarini, C. M. (2009). Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr. Opin. Investig. Drugs 10, 1359-1371.
65. Galsky, M. D., Dritselis, A., Kirkpatrick, P., and Oh, W. K. (2010). Cabazitaxel. Nat. Rev. Drug Discov. 9, 677-678.
66. Gascoigne, K. E., and Taylor, S. S. (2008). Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122.
67. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., Skarlos, D., Campone, M., Davidson, N., Berger, M., Oliva, C., Rubin, S. D., Stein, S., and Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743.
68. Gilmartin, A. G., Bleam, M. R., Richter, M. C., Erskine, S. G., Kruger, R. G., Madden, L., Hassler, D. F., Smith, G. K., Gontarek, R. R., Courtney, M. P., Sutton, D., Diamond, M. A., Jackson, J. R., and Laquerre, S. G. (2009). Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 69, 6969-6977.
69. Girnun, G. D., Chen, L., Silvaggi, J., Drapkin, R., Chirieac, L. R., Padera, R. F., Upadhyay, R., Vafai, S. B., Weissleder, R., Mahmood, U., Naseri, E., Buckley, S., Li, D., Force, J., McNamara, K., Demetri, G., Spiegelman, B. M., and Wong, K. K. (2008). Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res. 14, 6478-6486.
70. Gockel, H. R., Lugering, A., Heidemann, J., Schmidt, M., Domschke, W., Kucharzik, T., and Lugering, N. (2004). Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol. 172, 5103-5109.
71. Goldstein, M., Roos, W. P., and Kaina, B. (2008). Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol. Appl. Pharmacol. 229, 20-32.
72. Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001). Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663.
73. Goossens, V., Grooten, J., De Vos, K., and Fiers, W. (1995). Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 92, 8115-8119.
74. Goossens, V., Grooten, J., and Fiers, W. (1996). The oxidative metabolism of glutamine. A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells. J. Biol. Chem. 271, 192-196.
75. Goossens, V., Stange, G., Moens, K., Pipeleers, D., and Grooten, J. (1999). Regulation of tumor necrosis factor-induced, mitochondria-and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. Antioxid. Redox Signal. 1, 285-295.
76. Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S. H., Haanen, J., Castellano, D., Vrdoljak, E., Schöffski, P., Mainwaring, P., Nieto, A., Yuan, J., and Bukowski, R. (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757-763.
77. Gourdier, I., Crabbe, L., Andreau, K., Pau, B., and Kroemer, G. (2004). Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23, 7449-7457.
78. Gradishar, W. J. (2011). The place for eribulin in the treatment of metastatic breast cancer. Curr. Oncol. Rep. 13, 11-16.
79. Gralla, R. J., Gatzemeier, U., Gebbia, V., Huber, R., O'Brien, M., and Puozzo, C. (2007). Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67, 1403-1410.
80. Green, D. R., Ferguson, T., Zitvogel, L., and Kroemer, G. (2009). Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353-363.
81. Guchelaar, H. J., Vermes, I., Koopmans, R. P., Reutelingsperger, C. P., and Haanen, C. (1998). Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother. Pharmacol. 42, 77-83.
82. Guerrouahen, B. S., Futami, M., Vaklavas, C., Kanerva, J., Whichard, Z. L., Nwawka, K., Blanchard, E. G., Lee, F. Y., Robinson, L. J., Arceci, R., Kornblau, S. M., Wieder, E., Cayre, Y. E., and Corey, S. J. (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin. Cancer Res. 16, 1149-1158.
83. Gumireddy, K., Reddy, M. V., Cosenza, S. C., Boominathan, R., Baker, S. J., Papathi, N., Jiang, J., Holland, J., and Reddy, E. P. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275-286.
84. Han, W., Li, L., Qiu, S., Lu, Q., Pan, Q., Gu, Y., Luo, J., and Hu, X. (2007). Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol. Cancer Ther. 6, 1641-1649.
85. Harley, M. E., Allan, L. A., Sanderson, H. S., and Clarke, P. R. (2010). Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 29, 2407-2420.
86. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J. M., and Miller, K. M. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262-267.
87. He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., and Wang, X. (2009). Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100-1111.
88. Hewitt, L., Tighe, A., Santaguida, S., White, A. M., Jones, C. D., Musacchio, A., Green, S., and Taylor, S. S. (2010). Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J. Cell Biol. 190, 25-34.
89. Hirt, U. A., and Leist, M. (2003). Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differ. 10, 1156-1164.
90. Hitomi, J., Christofferson, D. E., Ng, A., Yao, J., Degterev, A., Xavier, R. J., and Yuan, J. (2008). Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135, 1311-1323.
91. Hoar, K., Chakravarty, A., Rabino, C., Wysong, D., Bowman, D., Roy, N., and Ecsedy, J. A. (2007). MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol. Cell. Biol. 27, 4513-4525.
92. Hoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., Panaretakis, T., Siemeister, G., Lage, H., Nanty, L., Hammer, S., Mittelstaedt, K., Winsel, S., Eschenbrenner, J., Castedo, M., Demarche, C., Klar, U., and Kroemer, G. (2008). Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res. 68, 5301-5308.
93. Hortelano, S., and Bosca, L. (1997). 6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Mol. Pharmacol. 51, 414-421.
94. Howell, A. (2005). Adjuvant aromatase inhibitors for breast cancer. Lancet 366, 431-433.
95. Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J. F., Hoctin-Boes, G., Houghton, J., Locker, G. Y., and Tobias, J. S. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62.
96. Hoy, S. M., and Wagstaff, A. J. (2006). Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 66, 2005-2014; discussion 2015-2006.
97. Hu, X., and Xuan, Y. (2008). Bypassing cancer drug resistance by activating multiple death pathways-a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259, 127-137.
98. Huang, S., Shu, L., Easton, J., Harwood, F. C., Germain, G. S., Ichijo, H., and Houghton, P. J. (2004). Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem. 279, 36490-36496.
99. Huang, W. Y., Yang, P. M., Chang, Y. F., Marquez, V. E., and Chen, C. C. (2011). Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem. Pharmacol. 81, 510-517.
100. Huang, Y. F., Chang, M. D., and Shieh, S. Y. (2009). TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Mol. Cell. Biol. 29, 2935-2944.
101. Huck, J. J., Zhang, M., McDonald, A., Bowman, D., Hoar, K. M., Stringer, B., Ecsedy, J., Manfredi, M. G., and Hyer, M. L. (2010). MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 8, 373-384.
102. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., Kovacevic, Z., Lesovoy, V., Schmidt-Wolf, I. G., Barbarash, O., Gokmen, E., O'Toole, T., Lustgarten, S., Moore, L., Motzer, R. J. and Global ARCC Trial. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281.
103. Hudis, C. A. (2007). Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51.
104. Huszar, D., Theoclitou, M. E., Skolnik, J., and Herbst, R. (2009). Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev. 28, 197-208.
105. Hwang, P. M., Bunz, F., Yu, J., Rago, C., Chan, T. A., Murphy, M. P., Kelso, G. F., Smith, R. A., Kinzler, K. W., and Vogelstein, B. (2001). Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med. 7, 1111-1117.
106. Iacobini, M., Menichelli, A., Palumbo, G., Multari, G., Werner, B., and Del Principe, D. (2001). Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells. Biochem. Pharmacol. 61, 1033-1040.
107. Jaglowski, S. M., Alinari, L., Lapalombella, R., Muthusamy, N., and Byrd, J. C. (2010). The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116, 3705-3714.
108. Jani, J. P., Arcari, J., Bernardo, V., Bhattacharya, S. K., Briere, D., Cohen, B. D., Coleman, K., Christensen, J. G., Emerson, E. O., Jakowski, A., Hook, K., Los, G., Moyer, J. D., Pruimboom-Brees, I., Pustilnik, L., Rossi, A. M., Steyn, S. J., Su, C., Tsaparikos, K., Wishka, D., Yoon, K., and Jakubczak, J. L. (2010). PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol. Cancer Ther. 9, 883-894.
109. Jayadev, S., Hayter, H. L., Andrieu, N., Gamard, C. J., Liu, B., Balu, R., Hayakawa, M., Ito, F., and Hannun, Y. A. (1997). Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells. J. Biol. Chem. 272, 17196-17203.
110. Ji, C., Yang, B., Yang, Y. L., He, S. H., Miao, D. S., He, L., and Bi, Z. G. (2010). Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 29, 6557-6568.
111. Joel, S. (1996). The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Cancer Treat. Rev. 21, 513-525.
112. Joza, N., Oudit, G. Y., Brown, D., Benit, P., Kassiri, Z., Vahsen, N., Benoit, L., Patel, M. M., Nowikovsky, K., Vassault, A., Backx, P. H., Wada, T., Kroemer, G., Rustin, P., and Penninger, J. M. (2005). Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol. Cell. Biol. 25, 10261-10272.
113. Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y., Sasaki, T., Elia, A. J., Cheng, H. Y., Ravagnan, L., Ferri, K. F., Zamzami, N., Wakeham, A., Hakem, R., Yoshida, H., Kong, Y. Y., Mak, T. W., Zúñiga-Pflücker, J. C., Kroemer, G., and Penninger, J. M. (2001). Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410, 549-554.
114. Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., Kappel, S., Janschek, E., Wenzel, C., Schlagbauer-Wadl, H., Mittlbock, M., Gnant, M., Steger, G., and Jakesz, R. (2000). TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6, 50-56.
115. Kanthou, C., and Tozer, G. M. (2007). Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin. Ther. Targets 11, 1443-1457.
116. Karpinich, N. O., Tafani, M., Rothman, R. J., Russo, M. A., and Farber, J. L. (2002). The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J. Biol. Chem. 277, 16547-16552.
117. Kelly, J. D., Williamson, K. E., Weir, H. P., McManus, D. T., Hamilton, P. W., Keane, P. F., and Johnston, S. R. (2000). Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer. BJU Int. 85, 911-917.
118. Kepp, O., Galluzzi, L., Zitvogel, L., and Kroemer, G. (2010). Pyroptosis-a cell death modality of its kind? Eur. J. Immunol. 40, 627-630.
119. Kerr, J. F. (1965). A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J. Pathol. Bacteriol. 90, 419-435.
120. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
121. Ketley, N. J., Allen, P. D., Kelsey, S. M., and Newland, A. C. (1997). Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1, 25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Blood 90, 4578-4587.
122. Kim, Y. S., Morgan, M. J., Choksi, S., and Liu, Z. G. (2007). TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell 26, 675-687.
123. Kitzen, J. J., de Jonge, M. J., and Verweij, J. (2010). Aurora kinase inhibitors. Crit. Rev. Oncol. Hematol. 73, 99-110.
124. Koyama, M., Izutani, Y., Goda, A. E., Matsui, T. A., Horinaka, M., Tomosugi, M., Fujiwara, J., Nakamura, Y., Wakada, M., Yogosawa, S., Sowa, Y., and Sakai, T. (2010). Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin. Cancer Res. 16, 2320-2332.
125. Kroemer, G., Galluzzi, L., and Brenner, C. (2007). Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163.
126. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nuñez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., Melino, G., and Nomenclature Committee on Cell Death. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16, 3-11.
127. Kroemer, G., and Levine, B. (2008). Autophagic cell death: the story of a misnomer. Nat. Rev. Mol. Cell Biol. 9, 1004-1010.
128. Krumschnabel, G., Sohm, B., Bock, F., Manzl, C., and Villunger, A. (2009). The enigma of caspase-2: the laymen's view. Cell Death Differ. 16, 195-207.
129. Krysko, D. V., Brouckaert, G., Kalai, M., Vandenabeele, P., and D'Herde, K. (2003). Mechanisms of internalization of apoptotic and necrotic L929 cells by a macrophage cell line studied by electron microscopy. J. Morphol. 258, 336-345.
130. Krysko, D. V., Denecker, G., Festjens, N., Gabriels, S., Parthoens, E., D'Herde, K., and Vandenabeele, P. (2006). Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ. 13, 2011-2022.
131. Krysko, O., De Ridder, L., and Cornelissen, M. (2004). Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labeling technique. Apoptosis 9, 495-500.
132. Kwiatkowski, N., Jelluma, N., Filippakopoulos, P., Soundararajan, M., Manak, M. S., Kwon, M., Choi, H. G., Sim, T., Deveraux, Q. L., Rottmann, S., Pellman, D., Shah, J. V., Kops, G. J., Knapp, S., and Gray, N. S. (2010). Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat. Chem. Biol. 6, 359-368.
133. Lad, L., Luo, L., Carson, J. D., Wood, K. W., Hartman, J. J., Copeland, R. A., and Sakowicz, R. (2008). Mechanism of inhibition of human KSP by ispinesib. Biochemistry 47, 3576-3585.
134. Lanza, L., Scudeletti, M., Puppo, F., Bosco, O., Peirano, L., Filaci, G., Fecarotta, E., Vidali, G., and Indiveri, F. (1996). Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin. Exp. Immunol. 103, 482-490.
135. Lauber, K., Bohn, E., Krober, S. M., Xiao, Y. J., Blumenthal, S. G., Lindemann, R. K., Marini, P., Wiedig, C., Zobywalski, A., Baksh, S., Xu, Y., Autenrieth, I. B., Schulze-Osthoff, K., Belka, C., Stuhler, G., and Wesselborg, S. (2003). Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113, 717-730.
136. Laurent, G., and Jaffrezou, J. P. (2001). Signaling pathways activated by daunorubicin. Blood 98, 913-924.
137. Law, C. L., Gordon, K. A., Collier, J., Klussman, K., McEarchern, J. A., Cerveny, C. G., Mixan, B. J., Lee, W. P., Lin, Z., Valdez, P., Wahl, A. F., and Grewal, I. S. (2005). Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65, 8331-8338.
138. Lee, J. J., and Swain, S. M. (2008). The epothilones: translating from the laboratory to the clinic. Clin. Cancer Res. 14, 1618-1624.
139. Lens, S. M., Voest, E. E., and Medema, R. H. (2010). Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825-841.
140. Lettre, G., and Hengartner, M. O. (2006). Developmental apoptosis in C. elegans: a complex CEDnario. Nat. Rev. Mol. Cell Biol. 7, 97-108.
141. Li, L., Tanaka, T., Yukawa, K., Akira, S., and Umesaki, N. (2009). Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase. Int. J. Oncol. 34, 905-914.
142. Ling, Y. H., Lin, R., and Perez-Soler, R. (2008). Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol. Pharmacol. 74, 793-806.
143. Lisztwan, J., Pornon, A., Chen, B., Chen, S., and Evans, D. B. (2008). The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res. 10, R56.
144. Llobet, D., Eritja, N., Yeramian, A., Pallares, J., Sorolla, A., Domingo, M., Santacana, M., Gonzalez-Tallada, F. J., Matias-Guiu, X., and Dolcet, X. (2010). The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur. J. Cancer 46, 836-850.
145. Lo, Y. L., Ho, C. T., and Tsai, F. L. (2008). Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur. J. Pharm. Sci. 35, 52-67.
146. Lockshin, R. A., and Williams, C. M. (1964). Programmed cell death-II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J. Insect Physiol. 10, 643-649.
147. Lou, P. J., Jager, H. R., Jones, L., Theodossy, T., Bown, S. G., and Hopper, C. (2004). Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br. J. Cancer 91, 441-446.
148. Ma, C. X., Janetka, J. W., and Piwnica-Worms, H. (2011). Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends. Mol. Med. 17, 88-96.
149. Mahalingam, D., Medina, E. C., Esquivel, J. A. II, Espitia, C. M., Smith, S., Oberheu, K., Swords, R., Kelly, K. R., Mita, M. M., Mita, A. C., Carew, J. S., Giles, F. J., and Nawrocki, S. T. (2010). Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153.
150. Majsterek, I., Gloc, E., Blasiak, J., and Reiter, R. J. (2005). A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J. Pineal Res. 38, 254-263.
151. Marchi, E., Paoluzzi, L., Scotto, L., Seshan, V. E., Zain, J. M., Zinzani, P. L., and O'Connor, O. A. (2010). Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin. Cancer Res. 16, 3648-3658.
152. Marignani, M., Angeletti, S., and delle Fave, G. (2009). Monoclonal antibody therapy and non-Hodgkin's lymphoma. N. Engl. J. Med. 360, 192-193; author reply 193.
153. Marneros, A. G., Grossman, M. E., Silvers, D. N., Husain, S., Nuovo, G. J., MacGregor-Cortelli, B., Neylon, E., Patterson, M., O'Connor, O. A., and Zain, J. M. (2009). Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood 113, 6338-6341.
154. Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., and Green, D. R. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182, 1545-1556.
155. McLaughlin, J., Markovtsov, V., Li, H., Wong, S., Gelman, M., Zhu, Y., Franci, C., Lang, D. W., Pali, E., Lasaga, J., Lasaga, J., Low, C., Zhao, F., Chang, B., Gururaja, T. L., Xu, W., Baluom, M., Sweeny, D., Carroll, D., Sran, A., Thota, S., Parmer, M. Romane, A., Clemens, G., Grossbard, E., Qu, K., Jenkins, Y., Kinoshita, T., Taylor, V., Holland, S. J., Argade, A., Singh, R., Pine, P., Payan, D. G., Hitoshi, Y. (2009). Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J. Cancer Res. Clin. Oncol. 136, 99-113.
156. Metzger-Filho, O., Moulin, C., de Azambuja, E., and Ahmad, A. (2009). Larotaxel: broadening the road with new taxanes. Expert Opin. Investig. Drugs 18, 1183-1189.
157. Mi, J., Bolesta, E., Brautigan, D. L., and Larner, J. M. (2009). PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53. Mol. Cancer Ther. 8, 135-140.
158. Miele, E., Spinelli, G. P., Tomao, F., and Tomao, S. (2009). Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 4, 99-105.
159. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., and Anderson, K. C. (2002). Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525-4530.
160. Mohsin, S. K., Weiss, H. L., Gutierrez, M. C., Chamness, G. C., Schiff, R., Digiovanna, M. P., Wang, C. X., Hilsenbeck, S. G., Osborne, C. K., Allred, D. C., Elledge, R., and Chang, J. C. (2005). Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 23, 2460-2468.
161. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., and Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957.
162. Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., Flick, S. M., Hartman, P. H., Ortiz, J. D., Lavertu, P. N., and Remick, S. C. (2009). A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19, 233-240.
163. Moore, C. M., Pendse, D., and Emberton, M. (2009). Photodynamic therapy for prostate cancer-a review of current status and future promise. Nat. Clin. Pract. Urol. 6, 18-30.
164. Mori-Abe, A., Tsutsumi, S., Takahashi, K., Toya, M., Yoshida, M., Du, B., Kawagoe, J., Nakahara, K., Takahashi, T., Ohmichi, M., and Kurachi, H. (2003). Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 178, 417-426.
165. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grunwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Urbanowitz, G., Berg, W. J., Kay, A., Lebwohl, D., Ravaud, A., RECORD-1 Study Group. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456.
166. Moubarak, R. S., Yuste, V. J., Artus, C., Bouharrour, A., Greer, P. A., Menissier-de Murcia, J., and Susin, S. A. (2007). Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol. Cell. Biol. 27, 4844-4862.
167. Musacchio, A., and Salmon, E. D. (2007). The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8, 379-393.
168. Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Kinoyama, I., Matsuhisa, A., Kudou, M., and Sasamata, M. (2011). Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102, 614-621.
169. Nakashio, A., Fujita, N., Rokudai, S., Sato, S., and Tsuruo, T. (2000). Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 60, 5303-5309.
170. Nazarewicz, R. R., Zenebe, W. J., Parihar, A., Larson, S. K., Alidema, E., Choi, J., and Ghafourifar, P. (2007). Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 67, 1282-1290.
171. Niesvizky, R., Ely, S., Mark, T., Aggarwal, S., Gabrilove, J. L., Wright, J. J., Chen-Kiang, S., and Sparano, J. A. (2011). Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117, 336-342.
172. Nishioka, C., Ikezoe, T., Yang, J., Koeffler, H. P., and Taguchi, H. (2007). Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway. Leukemia 21, 1044-1049.
173. Niu, G., Sun, X., Cao, Q., Courter, D., Koong, A., Le, Q. T., Gambhir, S. S., and Chen, X. (2010). Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin. Cancer Res. 16, 2095-2105.
174. Nuckel, H., Frey, U. H., Roth, A., Duhrsen, U., and Siffert, W. (2005). Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur. J. Pharmacol. 514, 217-224.
175. Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., and Von Hoff, D. D. (2005). Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785-7793.
176. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., Métivier, D., Larochette, N., van Endert, P., Ciccosanti, F., Piacentini, M., Zitvogel, L., and Kroemer, G. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61.
177. Obrero, M., Yu, D. V., and Shapiro, D. J. (2002). Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem. 277, 45695-45703.
178. Olaussen, K. A., Commo, F., Tailler, M., Lacroix, L., Vitale, I., Raza, S. Q., Richon, C., Dessen, P., Lazar, V., Soria, J. C., and Kroemer, G. (2009). Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28, 4249-4260.
179. O'Reilly, T., Wartmann, M., Brueggen, J., Allegrini, P. R., Floersheimer, A., Maira, M., and McSheehy, P. M. (2008). Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother. Pharmacol. 62, 1045-1054.
180. Paesler, J., Gehrke, I., Gandhirajan, R. K., Filipovich, A., Hertweck, M., Erdfelder, F., Uhrmacher, S., Poll-Wolbeck, S. J., Hallek, M., and Kreuzer, K. A. (2010). The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res. 16, 3390-3398.
181. Palucka, K. A., Knaust, E., Xu, D., Macnamara, B., Porwit-Macdonald, A., Gruber, A., Peterson, C., Bjorkholm, M., and Pisa, P. (1999). Intraclonal heterogeneity in the in vitro daunorubicin-induced apoptosis in acute myeloid leukemia. Leuk. Lymphoma 32, 309-316.
182. Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., Yuan, J., Zitvoge, L., Madeo, F., Williams, D. B., and Kroemer, G. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578-590.
183. Panda, D., Miller, H. P., Islam, K., and Wilson, L. (1997). Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. U.S.A. 94, 10560-10564.
184. Park, I. C., Park, M. J., Hwang, C. S., Rhee, C. H., Whang, D. Y., Jang, J. J., Choe, T. B., Hong, S. I., and Lee, S. H. (2000). Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 158, 125-132.
185. Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O'Reilly, L. A., Waterhouse, N. J., Trapani, J. A., and Johnstone, R. W. (2003). Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460-4471.
186. Perez, E. A. (2009). Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther. 8, 2086-2095.
187. Perez Fidalgo, J. A., Roda, D., Rosello, S., Rodriguez-Braun, E., and Cervantes, A. (2009). Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clin. Transl. Oncol. 11, 787-798.
188. Pette, M., Gold, R., Pette, D. F., Hartung, H. P., and Toyka, K. V. (1995). Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology 30, 59-69.
189. Pirnia, F., Schneider, E., Betticher, D. C., and Borner, M. M. (2002). Mitomycin C induces apoptosis and caspase-8 and-9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ. 9, 905-914.
190. Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M., and Strasser, A. (1999). The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287-296.
191. Puthalakath, H., Villunger, A., O'Reilly, L. A., Beaumont, J. G., Coultas, L., Cheney, R. E., Huang, D. C., and Strasser, A. (2001). Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829-1832.
192. Rigas, A., Dervenis, C., Giannakou, N., Kozoni, V., Shiff, S. J., and Rigas, B. (2002). Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans. Cancer Invest. 20, 657-665.
193. Riggins, R. B., Zwart, A., Nehra, R., and Clarke, R. (2005). The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol. Cancer Ther. 4, 33-41.
194. Rivera, E., Lee, J., and Davies, A. (2008). Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13, 1207-1223.
195. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., Wang, Y., and Chang, C. H. (2008). Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 68, 8384-8392.
196. Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., and Adolf, G. R. (2009). BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094-3102.
197. Ryan, B. M., O'Donovan, N., and Duffy, M. J. (2009). Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 35, 553-562.
198. Sakoe, Y., Sakoe, K., Kirito, K., Ozawa, K., and Komatsu, N. (2010). FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood 115, 3787-3795.
199. Sampath, D., Discafani, C. M., Loganzo, F., Beyer, C., Liu, H., Tan, X., Musto, S., Annable, T., Gallagher, P., Rios, C., and Greenberger, L. M. (2003). MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol. Cancer Ther. 2, 873-884.
200. Sanchez-Alcazar, J. A., Bradbury, D. A., Brea-Calvo, G., Navas, P., and Knox, A. J. (2003). Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression. Apoptosis 8, 639-647.
201. Santaguida, S., Tighe, A., D'Alise, A. M., Taylor, S. S., and Musacchio, A. (2010). Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J. Cell Biol. 190, 73-87.
202. Sarli, V., and Giannis, A. (2008). Targeting the kinesin spindle protein: basic principles and clinical implications. Clin. Cancer Res. 14, 7583-7587.
203. Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., Gabriele, L., Proietti, E., and Bracci, L. (2011). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71, 768-778.
204. Schiffer, C. A. (2007). BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 357, 258-265.
205. Schmidt, M., Budirahardja, Y., Klompmaker, R., and Medema, R. H. (2005). Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep. 6, 866-872.
206. Schweichel, J. U., and Merker, H. J. (1973). The morphology of various types of cell death in prenatal tissues. Teratology 7, 253-266.
207. Schwerdt, G., Freudinger, R., Schuster, C., Weber, F., Thews, O., and Gekle, M. (2005). Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. Toxicol. Sci. 85, 735-742.
208. Shan, D., Gopal, A. K., and Press, O. W. (2001). Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin. Cancer Res. 7, 2490-2495.
209. Sharma, S., and Lichtenstein, A. (2008). Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 112, 1338-1345.
210. Shi, J., Tricot, G. J., Garg, T. K., Malaviarachchi, P. A., Szmania, S. M., Kellum, R. E., Storrie, B., Mulder, A., Shaughnessy, J. D., Jr., Barlogie, B., and van Rhee, F. (2008). Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111, 1309-1317.
211. Shinzawa, K., and Tsujimoto, Y. (2003). PLA2 activity is required for nuclear shrinkage in caspase-independent cell death. J. Cell Biol. 163, 1219-1230.
212. Smolewski, P. (2008). Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 11, 204-214.
213. Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., Gurtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N., Peters, J. M., and Rettig, W. J. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322.
214. Stein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I. D., Hansen, H. J., and Goldenberg, D. M. (2004). Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10, 2868-2878.
215. Sun, X., Li, Y., Li, W., Zhang, B., Wang, A. J., Sun, J., Mikule, K., Jiang, Z., and Li, C. J. (2006). Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle 5, 2029-2035.
216. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T. T., Huang, F., Decillis, A. P., and Sawyers, C. L. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541.
217. Temkin, V., Huang, Q., Liu, H., Osada, H., and Pope, R. M. (2006). Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol. Cell. Biol. 26, 2215-2225.
218. Terrano, D. T., Upreti, M., and Chambers, T. C. (2010). Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 30, 640-656.
219. Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., Mendiboure, J.-P., Pignon, V., Jooste, P., van Endert, M., Ducreux, L., Zitvogel, F. P., and Kroemer, G. (2010). Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491.
220. Thiantanawat, A., Long, B. J., and Brodie, A. M. (2003). Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63, 8037-8050.
221. Thomas, A., Pepper, C., Hoy, T., and Bentley, P. (2000). Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. Leuk. Res. 24, 813-821.
222. Thon, L., Mohlig, H., Mathieu, S., Lange, A., Bulanova, E., Winoto-Morbach, S., Schutze, S., Bulfone-Paus, S., and Adam, D. (2005). Ceramide mediates caspase-independent programmed cell death. FASEB J. 19, 1945-1956.
223. Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., and Janne, P. A. (2004). Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64, 7241-7244.
224. Traganos, F., Seiter, K., Feldman, E., Halicka, H. D., and Darzynkiewicz, Z. (1996). Induction of apoptosis by camptothecin and topotecan. Ann. N.Y. Acad. Sci. 803, 101-110.
225. Twelves, C., Cortes, J., Vahdat, L. T., Wanders, J., Akerele, C., and Kaufman, P. A. (2010). Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10, 160-163.
226. Vakifahmetoglu, H., Olsson, M., and Zhivotovsky, B. (2008). Death through a tragedy: mitotic catastrophe. Cell Death Differ. 15, 1153-1162.
227. Vakifahmetoglu-Norberg, H., and Zhivotovsky, B. (2010). The unpredictable caspase-2: what can it do? Trends Cell Biol. 20, 150-159.
228. Van Cutsem, E., Kohne, C. H., Hitre, E., Zaluski, J., Chang Chien, C. R., Makhson, A., D'Haens, G., Pinter, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., and Rougier, P. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417.
229. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J. L., Van Laethem, J. L., Maurel, J., Richardson, G., Wolf, M., and Amado, R. G. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664.
230. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010). Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700-714.
231. VanderPorten, E. C., Taverna, P., Hogan, J. N., Ballinger, M. D., Flanagan, W. M., and Fucini, R. V. (2009). The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol. Cancer Ther. 8, 930-939.
232. Vanlangenakker, N., Vanden Berghe, T., Bogaert, P., Laukens, B., Zobel, K., Deshayes, K., Vucic, D., Fulda, S., Vandenabeele, P., and Bertrand, M. J. (2011). cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18, 656-665.
233. Vidot, S., Witham, J., Agarwal, R., Greenhough, S., Bamrah, H. S., Tigyi, G. J., Kaye, S. B., and Richardson, A. (2010). Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell. Signal. 22, 926-935.
234. Vigneri, P., and Wang, J. Y. (2001). Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7, 228-234.
235. Vitale, I., Galluzzi, L., Senovilla, L., Criollo, A., Jemaa, M., Castedo, M., and Kroemer, G. (2011). Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ. doi: 10.1038/cdd.2010.145
236. Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., Castedo, M., and Kroemer, G. (2007). Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS ONE 2, e1337. doi: 10.1371/journal.pone.0001337
237. Vrana, J. A., Wang, Z., Rao, A. S., Tang, L., Chen, J. H., Kramer, L. B., and Grant, S. (1999). Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia 13, 1046-1055.
238. Wagner, C. E., Jurutka, P. W., Marshall, P. A., Groy, T. L., van der Vaart, A., Ziller, J. W., Furmick, J. K., Graeber, M. E., Matro, E., Miguel, B. V., Tran, I. T., Kwon, J., Tedeschi, J. N., Moosavi, S., Danishyar, A., Philp, J. S., Khamees, R. O., Jackson, J. N., Grupe, D. K., Badshah, S. L., and Hart, J. W. (2009). Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). J. Med. Chem. 52, 5950-5966.
239. Wajant, H. (2002). The Fas signaling pathway: more than a paradigm. Science 296, 1635-1636.
240. Wang, S., Konorev, E. A., Kotamraju, S., Joseph, J., Kalivendi, S., and Kalyanaraman, B. (2004). Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms intermediacy of H(2)O(2)-and p53-dependent pathways. J. Biol. Chem. 279, 25535-25543.
241. Warrell, R. P. Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., and Jakubowski, A. (1991). Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324, 1385-1393.
242. Watters, D. (1999). Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol. Cell Biol. 77, 263-271.
243. Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., Plehn, J., Doshi, A., Thomasson, D., McCarthy, N., Koeppen, H., Sherman, M., Zujewski, J., Camphausen, K., Chen, H., and Swain, S. M. (2006). Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769-777.
244. Whittaker, S. J., Demierre, M. F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., and Kim, Y. H. (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 4485-4491.
245. Wilkinson, R. W., Odedra, R., Heaton, S. P., Wedge, S. R., Keen, N. J., Crafter, C., Foster, J. R., Brady, M. C., Bigley, A., Brown, E., Byth, K. F., and Barrass, N. C. (2007). AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 13, 3682-3688.
246. Wisniewska-Jarosinska, M., Sliwinski, T., Kasznicki, J., Kaczmarczyk, D., Krupa, R., Bloch, K., Drzewoski, J., Chojnacki, J., Blasiak, J., and Morawiec-Sztandera, A. (2011). Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells. Mol. Biol. Rep. doi: 10.1007/s11033-010-0482-7
247. Woessner, R., Tunquist, B., Lemieux, C., Chlipala, E., Jackinsky, S., Dewolf, W., Jr., Voegtli, W., Cox, A., Rana, S., Lee, P., and Walker, D. (2009). ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 29, 4373-4380.
248. Won, J. S., and Singh, I. (2006). Sphingolipid signaling and redox regulation. Free Radic. Biol. Med. 40, 1875-1888.
249. Woo, S., Gardner, E. R., Chen, X., Ockers, S. B., Baum, C. E., Sissung, T. M., Price, D. K., Frye, R., Piekarz, R. L., Bates, S. E., and Figg, W. D. (2009). Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res. 15, 1496-1503.
250. Wood, K. W., Lad, L., Luo, L., Qian, X., Knight, S. D., Nevins, N., Brejc, K., Sutton, D., Gilmartin, A. G., Chua, P. R., Desai, R., Schauer, S. P., McNulty, D. E., Annan, R. S., Belmont, L. D., Garcia, C., Lee, Y., Diamond, M. A., Faucette, L. F., Giardiniere, M., Zhang, S., Sun, C. M., Vidal, J. D., Lichtsteiner, S., Cornwell, W. D., Greshock, J. D., Wooster, R. F., Finer, J. T., Copeland, R. A., Huang, P. S., Morgans, D. J. Jr., Dhanak, D., Bergnes, G., Sakowicz, R., and Jackson, J.R. (2010). Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc. Natl. Acad. Sci. U.S.A. 107, 5839-5844.
251. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., and Bartlett, J. B. (2008). lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 14, 4650-4657.
252. Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., and Yu, H. (2009). Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506-2513.
253. Xu, Y., and Villalona-Calero, M. A. (2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 13, 1841-1851.
254. 2+-dependent proteases in ischemic neuronal death: a conserved 'calpain-cathepsin cascade' from nematodes to primates. Cell Calcium 36, 285-293.
255. Yamashima, T., and Oikawa, S. (2009). The role of lysosomal rupture in neuronal death. Prog. Neurobiol. 89, 343-358.
256. Yamashima, T., Tonchev, A. B., Tsukada, T., Saido, T. C., Imajoh-Ohmi, S., Momoi, T., and Kominami, E. (2003). Sustained calpain activation associated with lysosomal rupture executes necrosis of the postischemic CA1 neurons in primates. Hippocampus 13, 791-800.
257. Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J. A., Tekmal, R. R., Petros, J., and Joshi, H. C. (1998). Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. U.S.A. 95, 1601-1606.
258. Yu, S. W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., and Dawson, V. L. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297, 259-263.
259. Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., Liu, D., Mouchet, E., Ready, S., Rosenthal, J. L., Queva, C., Schwartz, G. K., Taylor, K. J., Tse, A. N., Walker, G. E., and White, A. M. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955-2966.
260. Zermati, Y., Garrido, C., Amsellem, S., Fishelson, S., Bouscary, D., Valensi, F., Varet, B., Solary, E., and Hermine, O. (2001). Caspase activation is required for terminal erythroid differentiation. J. Exp. Med. 193, 247-254.
261. Zhang, D. W., Shao, J., Lin, J., Zhang, N., Lu, B. J., Lin, S. C., Dong, M. Q., and Han, J. (2009). RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332-336.
262. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q., and Thompson, C. B. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18, 1272-1282.